Nintedanib is a tyrosine kinase inhibitor that targets several additional growth factors implicated in IPF, namely PDGF, FGF, and vascular endothelial growth factor (VEGF). The gene discussed is VEGFA; the disease is idiopathic pulmonary fibrosis.